Minaris Advanced Therapies

We’re excited to welcome two new members to the Minaris Advanced Testing Business Development team: Heather Durant and Lisa Koenig. Heather Durant joins Minaris as Director, Business Development. Heather brings more than 20 years of experience across life sciences research, commercial sales, and CDMO services. Most recently at Northway Biotech and GenScript ProBio, she supported biologics and gene therapy programs from early development through commercialization. Earlier in her career, she held commercial leadership roles at Thermo Fisher Scientific and Bio-Rad, building deep expertise across molecular biology, qPCR, genomics, and biopharma markets. Heather’s combination of scientific foundation and strategic commercial experience positions her to support partners navigating complex development pathways. Lisa Koenig joins Minaris as Senior Business Development Manager – Testing Services. Lisa brings extensive experience in biopharma analytics and molecular technologies, with prior roles at QIAGEN and Bio-Rad Laboratories. She has worked closely with biotech and pharmaceutical teams to support dPCR, infectious disease testing, and advanced molecular workflows. With a strong background in genomics and commercial strategy, Lisa will focus on supporting sponsors across our biosafety, potency, viral clearance, and analytical testing services portfolio. Please join us in welcoming Heather and Lisa to the Minaris Advanced Testing team. #MinarisAdvancedTherapies #LifeSciences #BusinessDevelopment #CellAndGeneTherapy #BiosafetyTesting

Join us at the 9th Regenerative Medicine Seminar hosted by Shonan iPark on May 13. A member of our Yokohama site will share insights into the rental-type CPC model at Shonan iPark, operational since November 2025. This model enables skilled operators from each company to conduct manufacturing themselves — eliminating technology transfer while operating within a GMP/GCTP environment. We will discuss the concept, operational framework, and facility environment designed to accelerate the transition from R&D to clinical manufacturing.  We look forward to connecting with you during the on-site networking session. 🗓 May 13 (Wed) 16:00–18:30 JST  📍 Shonan iPark + Online (Hybrid)  💡 Seminar: Free | Networking (on-site): JPY 1,000    More information: https://lnkd.in/epWkRzXw    【セミナー登壇のお知らせ｜湘南アイパーク主催】  5月13日開催の「再生医療セミナー（第9回）」において、Minaris Advanced Therapies 横浜拠点のメンバーが登壇いたします。  2025年11月より運用を開始した湘南アイパークの賃貸型CPC。  本施設では、ハード面を湘南アイパークが、品質・施設管理システムを商用製造の実績を有するMinaris Advanced Therapiesが提供しています。  利用企業の熟練培養員が自ら製造を行うことで、技術移転を伴わずにGMP／GCTP環境下での治験製造を実現するモデルです。  本セミナーでは、研究開発段階から治験製造への移行を加速させる選択肢としての本モデルの構想背景、コンセプト、運用設計および施設環境についてお話しします。  当日は現地でネットワーキングの時間もございます。ぜひ直接ご質問・ご相談ください。  🗓 5月13日（水）16:00–18:30  📍 湘南アイパーク＋Zoom（ハイブリッド開催）  💡 セミナー参加無料（※現地ネットワーキング参加は1,000円）参加費無料   詳細は添付フライヤーをご覧ください。        #RegenerativeMedicine  #CellTherapy  #AdvancedTherapies  #CMC  #GMP  #GCTP  #ClinicalManufacturing  #CDMO  #ShonanIPark   

The Minaris team is on site in Rome at #CGMED26. Eytan Abraham, Corinne Branciaroli, and Amy Stewart are connecting with partners and innovators and enjoying engaging conversations around accelerating timelines, overcoming manufacturing challenges, and bringing life-changing therapies to patients faster. If you're attending, we’d love to connect. Reach out to any of our team members to arrange a time to meet. #CellAndGene #CGT #CellTherapy #GeneTherapy #Minaris #ARM

Centralized or decentralized CAR‑T manufacturing? Which model truly drives cost reduction? Which improves patient access? In a new Cytotherapy (ISCT) publication, Eytan Abraham and co-authors examine the operational and economic trade‑offs shaping the next phase of CAR‑T manufacturing. The paper explores cost breakdowns across models and challenges a common assumption: decentralization alone is unlikely to be the primary driver of cost reduction. Find out more here: https://lnkd.in/eG9mgzmS  #CAR-T #CellTherapy #ISCT #ManufacturingStrategy #AdvancedTherapies #CGT

Last week, we celebrated Laboratory Professionals Week at our Allendale and Philadelphia sites. With this year’s theme, “Lab Story: To Infinity and Beyond for Our Patients,” our teams marked the occasion with bingo, scavenger hunts, word finds, candy‑guessing games, and a few Toy Story‑inspired surprises, all organized by our Social Committees. Lab Week has become a meaningful (and fun!) tradition at our U.S. sites, a chance to recognize the vital role our laboratory professionals play in the healthcare ecosystem every day.  Thank you to the teams whose rigor, curiosity, and commitment power the science behind every program.  #LabWeek #LaboratoryProfessionals #LifeSciences #AdvancedTesting 

Heading to ISCT 2026? Let’s connect.    The Minaris team will be on site all week. Visit us at Booth #1806 or reach out to schedule time to discuss your CGT manufacturing success strategy.    On Thursday, May 7 (3:45–4:45 PM, Liffey Hall 2), join Eytan Abraham, Ph.D., Chief Commercial & Technology Officer, and Fernanda Masri, Global Head of Large Pharma, for From First Few to Commercial Supply: Early Decisions That Shape Autologous CGT Success.  This session will explore how early clinical decisions influence scalability, regulatory pathways, and long‑term commercial success — with live scenario discussion.    If you're building toward commercial supply, we’d welcome the conversation.    #ISCT2026 #CellAndGeneTherapy #AutologousTherapy #CGT #Manufacturing   

This past Thursday, we welcomed nearly 80 future scientists to our Allendale and Philadelphia sites for Take Your Child to Work Day. Company volunteers partnered with HR to create an interactive program introducing children to cell and gene therapy, advanced testing, and the work their parents do to deliver hope to patients. Opening our labs is a reminder that even cutting-edge science isn’t a black box. It’s people, purpose, and discovery. And in the future, perhaps it will include work conducted by these children.  #TakeYourChildToWorkDay #STEM #LifeSciences #Community 

Minaris has TEM capabilities in the U.S.? Yes, you heard that right. No customs. No paperwork. Just direct access — right here at the Minaris Advanced Testing site in Philadelphia. Our GMP Transmission Electron Microscopy (TEM) service provides direct visualization of adventitious and endogenous viruses to support: • Cell bank characterization  • Bulk harvest testing  • Viral safety strategies for mAbs, vaccines, and viral vectors  Integrated within our broader biosafety testing platform and backed by deep virology expertise, our U.S.-based TEM offering helps reduce logistical risk while keeping to your program's timeline. Learn more about how we can support your program.  https://lnkd.in/ejGTBtep  #TEM #ViralSafety #BiosafetyTesting #CellAndGeneTherapy #Biologics #MinarisAdvancedTesting 

We’re heading to ASGCT 2026, and we’re bringing new findings. Visit us at booth #939. We’ll also be presenting three scientific posters. • LVV yield intensification with XOFLX™  • Cargo gene silencing to boost LVV and AAV production  • TESSA® platform enabling scalable, lower‑cost AAV manufacturing  From yield to cost‑of‑goods, our focus is making advanced therapies more manufacturable. See you in Boston where the Minaris team will include Shari Udoff-McDonald, Yukari Tokuyama, Francesca Vitelli, Joseph Newcome, Venus Wenxin Huang, Ph.D., Emmanuelle Bommier, Mike Hammerman, Nithya Jesuraj, PhD, Delphine Caraguel, Qian Liu, Meenakshi Raghunath, Vaughan Leydon Pavle Matak, Ph.D. Contact us to schedule a meeting https://lnkd.in/eKrjZUmA  #ASGCT2026 #CellAndGeneTherapy #AAV #Lentiviral #Biomanufacturing #CGT 

As cell therapy programs advance, consistent and reliable manufacturing is critical to keeping clinical development on track. That’s why we are proud to share a 100% manufacturing and release success rate in support of Chimeric Therapeutics’ CDH17-targeted autologous CAR-T program for gastrointestinal cancers. In close partnership with Chimeric, Minaris has delivered end-to-end GMP manufacturing and release testing over five years, maintaining a steady clinical cadence and ensuring dependable product supply for patients in an ongoing Phase 1A/1B study. Together, this work helps ensure patients receive consistent, high-quality therapies, supporting continued progress toward bringing new treatment options to those who need them most. View full details here: https://lnkd.in/eFSgWZyK #MinarisAdvancedTherapies #CellTherapy #CART #GMP #ClinicalTrials